Document series
Trial abstracts — page 25
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 25 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| CJC-PH1-ASCENDING-BODY-COMPprogramme record | CJC-1295 | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| CJC-PH1-ASCENDING-OLEprogramme record | CJC-1295 | Phase 1 | Reported | Single-arm open-label | — | 2006 | Very low |
| CJC-PH1-ASCENDING-QOLprogramme record | CJC-1295 | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| CJC-PH1-ASCENDING-REGIONAL-CNprogramme record | CJC-1295 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| CJC-PH1-ASCENDING-REGIONAL-JPprogramme record | CJC-1295 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| CJC-PH1-MULTIDOSE-DDIprogramme record | CJC-1295 | Phase 1 | Reported | Randomised crossover | — | 2006 | Very low |
| CJC-PH1-MULTIDOSE-HEPATIC-IMPprogramme record | CJC-1295 | Phase 1 | Reported | Phase 1 ascending dose | — | 2006 | Very low |
| CJC-PH1-MULTIDOSE-PKprogramme record | CJC-1295 | Phase 1 | Reported | Phase 1 ascending dose | — | 2006 | Very low |
| CJC-PH1-MULTIDOSE-RENAL-IMPprogramme record | CJC-1295 | Phase 1 | Reported | Phase 1 ascending dose | — | 2006 | Very low |
| GHRP2-JP-DIAGNOSTIC-BODY-COMPprogramme record | GHRP-2 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| GHRP2-JP-DIAGNOSTIC-PKprogramme record | GHRP-2 | Phase 1 | Reported | Phase 1 ascending dose | — | 2006 | Very low |
| GHRP2-JP-DIAGNOSTIC-QOLprogramme record | GHRP-2 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| GHRP2-JP-DIAGNOSTIC-REGIONAL-CNprogramme record | GHRP-2 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| GHRP2-JP-DIAGNOSTIC-REGIONAL-JPprogramme record | GHRP-2 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2006 | Very low |
| AMIGO-1-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2005 | Very low |
| AMIGO-1-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| AMIGO-1-PKprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| AMIGO-1-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2005 | Very low |
| AMIGO-1-RENAL-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| GHKCU-TOPICAL-1-DDIprogramme record | GHK-Cu | Phase 1 | Reported | Randomised crossover | — | 2005 | Very low |
| GHKCU-TOPICAL-1-HEPATIC-IMPprogramme record | GHK-Cu | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| GHKCU-TOPICAL-1-PKprogramme record | GHK-Cu | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| GHKCU-TOPICAL-1-RENAL-IMPprogramme record | GHK-Cu | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| TA1-HCV-1-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2004 | Very low |
page 25 of 30